A study published in the Journal of the American Academy of Orthopaedic Surgeons found that patients prescribed testosterone replacement therapy had nearly half the risk of hip fracture compared to those who didn’t receive TRT. The benefit was observed in both men and women, with women seeing an even greater relative risk reduction (aOR = 0.49).
The catch? There’s still no FDA-approved testosterone product for women, which means that for the millions who could benefit from therapy, compounded testosterone is often the only option. It’s yet another reminder of how essential compounding is to ensuring access to individualized, medically necessary care.